Experts Present Background on Long-Term Safety Study of Upadacitinib for AD


Christopher Bunick, MD, PhD, introduces an integrated analysis of phase three studies analyzing the long-term safety of upadacitinib as treatment for atopic dermatitis (AD). He also highlights a burgeoning standard to assess the safety of treatment.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.